ATL ULTRAMARK 9 WITH HDI: EXTENDED SIGNAL PROCESSING UPGRADE deliveries will begin in June, Advanced Technology Laboratories, Inc. says in an April 19 release. The ESP upgrade to the Ultramark 9 with High Definition Imaging uses real-time parallel processing and system software to reduce "speckle noise," an artifact caused by "the random, artificial pattern of overlapping ultrasound echoes," according to ATL. The ESP option is being offered as part of a "level four" upgrade that also includes the C7-4 broadband curved array scanhead, the fifth addition to ATL's broadband scanhead line. The C7-4 provides "superior image quality" in obstetrical, superficial abdominal, and pediatric ultrasound examinations, ATL claims. The firm explains that the ESP parallel processing module and system software work together to "optimize the entire image formation path and extract further tissue information from the HDI broadband digital beamformer, without the compromises to image resolution required by conventional methodologies." The technology "more than doubles signal processing," and the resulting reduction of speckle noise "expands the potential of ultrasound to address diagnostic applications that were previously the domain of exploratory surgery and other more expensive or invasive imaging modalities," according to the firm. Benefits claimed for ESP include "enhanced visualization of subtle masses and tumors, clearer depiction of tissue changes associated with disease processes, more well-defined interfaces and tissue boundaries, greater confidence in the assessment of lesions and enhanced color Doppler for improved visualization of flow." The technology also provides "greater clarity of vessels and fluid-filled structures" and "improved characterization of arterial and venous disease states," ATL says. In addition, the "resolution of extremely fine detail" offered by the technology helps with imaging of small anatomical structures and early visualization of fetal development processes, according to the firm.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.
Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.
The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.
